Immuron Ltd. operates as a microbiome biopharmaceutical company, which focuses on oral immunotherapy treatments using dairy-derived antibody products for humans. It operates through the following segments: Research and Development; HyperImmune Products; and Corporate. The Research and Development segment involves the research and development projects performed in Australia and Israel. The HyperImmune Products segment comprises of Travelan activities which occur in Australia, New Zealand, Canada, and the United States. The Corporate segment covers corporate activities. The company was founded on January 13, 1994 and is headquartered in Southbank, Australia.
|Market Price at 17-11-2017||$0.19|
|Price to Earnings Ratio||-4.22|
|Market Capitalisation||$24.71 (million)|
|Return on Equity (ROE)||-103.2%|